Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Recent advances in neuroimaging of Alzheimer's disease and related dementias

Ottoy, Julie ; Owsicki, Nicole ; Bilgel, Murat ; Binette, Alexa Pichet LU ; Salvadó, Gemma LU ; Kang, Min Su ; Cash, David M. ; Ewers, Michael ; La Joie, Renaud and Wisse, Laura E.M. LU orcid , et al. (2025) In Alzheimer's and Dementia 21(9).
Abstract

This review covers recent advances (2023–2024) in neuroimaging research into the pathophysiology, progression, and treatment of Alzheimer's disease (AD) and related dementias (ADRD). Despite the rapid emergence of blood-based biomarkers, neuroimaging continues to be a vital area of research in ADRD. Here, we discuss neuroimaging as a powerful tool to topographically visualize and quantify amyloid, tau, neurodegeneration, inflammation, and vascular disease in the brain. We examine the utility of neuroimaging for (1) tracking the spatiotemporal progression of pathology, (2) serving as the reference standard for validating novel fluid biomarkers, (3) characterizing disease heterogeneity, (4) exploring the role of brain networks in ADRD... (More)

This review covers recent advances (2023–2024) in neuroimaging research into the pathophysiology, progression, and treatment of Alzheimer's disease (AD) and related dementias (ADRD). Despite the rapid emergence of blood-based biomarkers, neuroimaging continues to be a vital area of research in ADRD. Here, we discuss neuroimaging as a powerful tool to topographically visualize and quantify amyloid, tau, neurodegeneration, inflammation, and vascular disease in the brain. We examine the utility of neuroimaging for (1) tracking the spatiotemporal progression of pathology, (2) serving as the reference standard for validating novel fluid biomarkers, (3) characterizing disease heterogeneity, (4) exploring the role of brain networks in ADRD progression, and (5) evaluating biomarkers for better individualized estimates of treatment benefit. Finally, we discuss advances in radiotracer development and AD risk factors. By reviewing the most promising breakthroughs in the neuroimaging field, we hope to spark new ideas for future discoveries that will deepen our understanding of ADRD. Highlights: The diagnostic and staging criteria for Alzheimer's disease (AD) were updated in 2024. Despite robust harmonization methods for amyloid beta positron emission tomography (PET), parallel efforts for tau PET remain challenging. Larger anti-amyloid drug effects were seen at lower levels of amyloid and tau PET. Phosphorylated tau217 (p-tau217) is currently the most promising plasma biomarker to detect AD pathology. There are new tracer developments for alpha-synuclein, primary tauopathies, and inflammation.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Alzheimer's disease, amyloid, cerebrospinal fluid biomarker, cerebrovascular disease, clinical trials, co-pathology, connectivity, disease staging and subtyping, heterogeneity, inflammation, neuroimaging, plasma biomarker, positron emission tomography, risk factors, tau
in
Alzheimer's and Dementia
volume
21
issue
9
article number
e70648
publisher
Wiley
external identifiers
  • scopus:105015142780
  • pmid:40922096
ISSN
1552-5260
DOI
10.1002/alz.70648
language
English
LU publication?
yes
id
c036e902-d203-470f-9f37-006c0bf5294a
date added to LUP
2025-10-16 11:16:58
date last changed
2025-11-13 13:17:47
@article{c036e902-d203-470f-9f37-006c0bf5294a,
  abstract     = {{<p>This review covers recent advances (2023–2024) in neuroimaging research into the pathophysiology, progression, and treatment of Alzheimer's disease (AD) and related dementias (ADRD). Despite the rapid emergence of blood-based biomarkers, neuroimaging continues to be a vital area of research in ADRD. Here, we discuss neuroimaging as a powerful tool to topographically visualize and quantify amyloid, tau, neurodegeneration, inflammation, and vascular disease in the brain. We examine the utility of neuroimaging for (1) tracking the spatiotemporal progression of pathology, (2) serving as the reference standard for validating novel fluid biomarkers, (3) characterizing disease heterogeneity, (4) exploring the role of brain networks in ADRD progression, and (5) evaluating biomarkers for better individualized estimates of treatment benefit. Finally, we discuss advances in radiotracer development and AD risk factors. By reviewing the most promising breakthroughs in the neuroimaging field, we hope to spark new ideas for future discoveries that will deepen our understanding of ADRD. Highlights: The diagnostic and staging criteria for Alzheimer's disease (AD) were updated in 2024. Despite robust harmonization methods for amyloid beta positron emission tomography (PET), parallel efforts for tau PET remain challenging. Larger anti-amyloid drug effects were seen at lower levels of amyloid and tau PET. Phosphorylated tau217 (p-tau217) is currently the most promising plasma biomarker to detect AD pathology. There are new tracer developments for alpha-synuclein, primary tauopathies, and inflammation.</p>}},
  author       = {{Ottoy, Julie and Owsicki, Nicole and Bilgel, Murat and Binette, Alexa Pichet and Salvadó, Gemma and Kang, Min Su and Cash, David M. and Ewers, Michael and La Joie, Renaud and Wisse, Laura E.M. and Goubran, Maged and Betthauser, Tobey}},
  issn         = {{1552-5260}},
  keywords     = {{Alzheimer's disease; amyloid; cerebrospinal fluid biomarker; cerebrovascular disease; clinical trials; co-pathology; connectivity; disease staging and subtyping; heterogeneity; inflammation; neuroimaging; plasma biomarker; positron emission tomography; risk factors; tau}},
  language     = {{eng}},
  number       = {{9}},
  publisher    = {{Wiley}},
  series       = {{Alzheimer's and Dementia}},
  title        = {{Recent advances in neuroimaging of Alzheimer's disease and related dementias}},
  url          = {{http://dx.doi.org/10.1002/alz.70648}},
  doi          = {{10.1002/alz.70648}},
  volume       = {{21}},
  year         = {{2025}},
}